19 Jul Diorasis Therapeutics Corporation
Remis Bistras, Ph.D., CEO
Oct. 11 | 4:45pm | Rentschler ATMP Ballroom
Boston, MA
(Private)
Diorasis Therapeutics is a preclinical stage company developing gene therapy for glaucoma (2.7M in the US, 80M WW). Non-compliance is the main issue of glaucoma treatment. 120K patients go blind in the US despite the availability of low-cost intraocular pressure lowering drops. Our disease-modifying gene agnostic single intracameral injection gene therapy produces tissue plasminogen activator (tPA) that normalizes trabecular meshwork outflow and IOP. Peak sales: $1.6-2B in the USA demonstrated significant efficacy:
-Mouse glaucoma model: outflow facility returned to normal, and IOP decreased to normal level after a single intracameral tPA GTx injection
-Sheep glaucoma model: a single intracameral tPA-producing GTx injection dramatically decreased IOP to normal levels lasting until the end of 6 weeks experiment without any observed safety concerns
-Normal mouse: no decrease in IOP (hypotony) after intracameral tPA GTx injection
Currently, we are conducting tox and IND-enabling studies to file IND.
